Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma

PURPOSE: Dexamethasone, a uniquely potent corticosteroid, is frequently administered to brain tumor patients to decrease tumor-associated edema, but limited data exist describing how dexamethasone affects the immune system systemically and intratumorally in glioblastoma patients – particularly in th...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Iorgulescu, J. Bryan, Gokhale, Prafulla C., Speranza, Maria C., Eschle, Benjamin K., Poitras, Michael J., Wilkens, Margaret K., Soroko, Kara M., Chhoeu, Chhayheng, Knott, Aine, Gao, Yan, Lim-Fat, Mary Jane, Baker, Gregory J., Bonal, Dennis M., Nguyen, Quang-Dé, Grant, Gareth R. L., Ligon, Keith L., Sorger, Peter K., Chiocca, E. Antonio, Anderson, Ana C., Kirschmeier, Paul T., Sharpe, Arlene H., Freeman, Gordon J., Reardon, David A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034990/
https://ncbi.nlm.nih.gov/pubmed/33239433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-2291
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak